Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval
The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it competes with a similar treatment from Biogen (BIIB) and Eisai. Read more... [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine
US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine.<br /> The article Eli Lilly signs $2.75 bill [...]
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s
Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]
The CES companies hoping your brain is the next big thing in computing
At every CES I’ve ever been to, there’s been one or two gadgets promising to boost your mental health. In recent years, the number of companies making forays into this space has grown, and will li [...]
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]
Apple has agreed to pay $20 million to settle a class action lawsuit over Apple Watch battery swelling
Owners of some early Apple Watch models may be eligible for payment from a $20 million class action settlement. Apple recently agreed to settle a lawsuit that claimed some first generation, Series 1, [...]
